Support Education Research
Please leave this field empty
Scleroderma Foundation
Homepage | Forward to a Friend | Make a Donation
eletter banner.jpg
eLetter #713 | May 26, 2017  

From This Year's American Thoracic Society Meeting in DC

ATS 2017Dr. Andy Tager (shown right) received the Recognition Award for Scientific Accomplishments at the annual American Thoracic Society meeting in Washington, DC, on May 21.

The Recognition Awards for Scientific Accomplishments is given to individuals for outstanding scientific contributions in basic or clinical research to the understanding, prevention and treatment of lung disease. Those considered for the award are recognized for either scientific contributions throughout their careers or for major contributions at a particular point in their careers.

Dr. Tager has contributed to our understanding of pathogenic mechanisms in fibrosis across different organs in scleroderma and related diseases. He gave an outstanding presentation summarizing his research work that has led to the development of potential therapies currently being tested in clinical trials.

Scleroderma Questions Answered from Cleveland Clinic Experts

Question MarkScleroderma experts from Cleveland Clinic discussed some common questions from patients. Dr. Kristin Highland, a pulmonologist who specializes in scleroderma-associated lung disease, and rheumatologist Dr. Soumya Chatterjee answered questions about fatigue, breathing problems and gut issues related to scleroderma.


What Is A Clinical Trial?

clinical trial.jpg

Interested in learning more about the clinical trial process? The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMSD) offers helpful information to introduce you to clinical trials.

Find out more about common terms in the glossary,  learn if clinical trials are right for you, and search for open trials currently accepting patients.


New EULAR Therapeutic Recommendations

StethoscopeThe European League Against Rheumatism (EULAR) has added two new therapeutic statements addressing organ complications in scleroderma, updated from the 2009 recommendations. These include Raynaud Phenomenon, digital ulcers, pulmonary arterial hypertension (PAH), skin and lung disease, scleroderma renal crisis, and gastrointestinal (GI) involvement. The new document increases the number of pharmacological management recommendations to 16.

Read more from MedPage Today >>

Quick Links
Contact Us
Become a Member
About Scleroderma
Calendar of Events
Online Chat
Make a gift
2016 Instagram

 actelion new.jpg
Bayer logo
Gilead Logo
reata small
Genentech Logo




Sencis Ad - eLetter

Disclaimer: The Scleroderma Foundation in no way endorses any drugs, treatments, clinical trials, or studies reported in the eLetter. Information is provided to keep the readers informed. Because the manifestations and severity of scleroderma vary among individuals, personalized medical management is essential. Therefore, it is strongly recommended that all drugs and treatments be discussed with the reader’s physician(s) for proper evaluation and treatment.

Powered by Blackbaud  Unsubscribe | Visit our web site | Contact Us | Donate
300 Rosewood Drive, Suite 105, Danvers, MA 01923 tel: 800-722-HOPE (4673)
© 2019 All rights reserved.